This work is licensed under the Creative Commons Attribution 4.0 International License.
Didkowska J, Wojciechowska U. Nowotwory złośliwe w Polsce w 2013 roku. Krajowy Rejestr Nowotworów. Warszawa 2015.DidkowskaJWojciechowskaUWarszawa2015Search in Google Scholar
Markowska A. Epidemiologia i etiopatogeneza raka jajnika W: Markowska J, Mądry R (Red.) Zarys Ginekologii Onkologicznej. Tom II. Termedia, Poznań, 2015.MarkowskaATermedia, Poznań2015Search in Google Scholar
Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E on behalf of the ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol 2016;27:103-110.Paluch-ShimonSCardosoFSessaCBalmanaJCardosoMJGilbertFSenkusEon behalf of the ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening20162710311010.1093/annonc/mdw327Search in Google Scholar
American College of Obstetricians and Gynecologists. Committee Opinion No. 620. Salpingectomy for ovarian cancer prevention. Obstet Gynecol 2015;125:279-281.American College of Obstetricians and GynecologistsCommittee Opinion No201512527928110.1097/01.AOG.0000459871.88564.09Search in Google Scholar
WHO Classification of Ovarian Neoplasms. PathologyOutlines. com: http://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html Dostęp: 01.10.2018.http://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.htmlDostęp: 01.10.2018Search in Google Scholar
Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008;9:1191-1197.DubeauLThe cell of origin of ovarian epithelial tumours200891191119710.1016/S1470-2045(08)70308-5Search in Google Scholar
Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012;10:296-306.ToneAASalvadorSFinlaysonSJTinkerAVKwonJSLeeCHCohenTEhlenTLeeMCareyMSet alThe role of the fallopian tube in ovarian cancer201210296306Search in Google Scholar
Kurman R, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory. Am J Surg Pathol 2010;33:433-443.KurmanRShihI-MThe origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory20103343344310.1097/PAS.0b013e3181cf3d79284179120154587Search in Google Scholar
Nik NN, Vang R, Shih I-M, Kurman RJ. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol Mech Dis 2014;9:2745.NikNNVangRShihI-MKurmanRJOrigin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma20149274510.1146/annurev-pathol-020712-16394923937438Search in Google Scholar
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for casual relationship. Am J Surg Pathol 2007;31:161-169.KindelbergerDWLeeYMironAHirschMSFeltmateCMedeirosFCallahanMJGarnerEOGordonRWBirchCet alIntraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for casual relationship20073116116910.1097/01.pas.0000213335.40358.4717255760Search in Google Scholar
Singh R, Cho KR. Serous tubal intraepithelial carcinoma or not? Metastases to fallopian tube mucosa can masquerade as in situ lesions. Arch Pathol Lab Med 2017;141:1313-1315.SinghRChoKRSerous tubal intraepithelial carcinoma or not? Metastases to fallopian tube mucosa can masquerade as in situ lesions20171411313131510.5858/arpa.2017-0231-RA28968160Search in Google Scholar
Trabert B, Coburn SB, Mariani A, Yang HP, Rosenberg PS, Gierach GL, Wentzensen N, Cronin KA, Sherman ME. Reported incidence and survival of fallopian tube carcinomas: a population-based analysis from the North American Association of Central Cancer Registries. J Natl Cancer Inst 2018;110:750-757.TrabertBCoburnSBMarianiAYangHPRosenbergPSGierachGLWentzensenNCroninKAShermanMEReported incidence and survival of fallopian tube carcinomas: a population-based analysis from the North American Association of Central Cancer Registries201811075075710.1093/jnci/djx263603712429281053Search in Google Scholar
Venturella R, Lico D, Borelli M, Imbrogno MG, Cevenini G, Zupi E, Zullo F, Morelli M. 3 to 5 years later: Long-term effects of prophylactic bilateral salpingectomy on ovarian function. J Minim Invasive Gynecol 2017;24:145-150.VenturellaRLicoDBorelliMImbrognoMGCeveniniGZupiEZulloFMorelliM3 to 5 years later: Long-term effects of prophylactic bilateral salpingectomy on ovarian function20172414515010.1016/j.jmig.2016.08.83327621194Search in Google Scholar
McAlpine JN, Hanley GE, Woo MMM, Tone AA, Rozenberg N, Swenerton KD, Gilks CB, Finlayson SJ, Huntsman DG, Miller DM for the Ovarian Cancer Research Program of British Columbia. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014;210:471. e1-471.e11.McAlpineJNHanleyGEWooMMMToneAARozenbergNSwenertonKDGilksCBFinlaysonSJHuntsmanDGMillerDM for the Ovarian Cancer Research Program of British Columbia.Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention2014210471e1-471.e1110.1016/j.ajog.2014.01.00324412119Search in Google Scholar
Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, D’Alessandro P, Zullo F. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: Primum non nocere. Gynecol Oncol 2013;129:448-451.MorelliMVenturellaRMocciaroRDiCello ARaniaELicoDD’AlessandroPZulloF.Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: Primum non nocere201312944845110.1016/j.ygyno.2013.03.02323558052Search in Google Scholar
Kwon JS. Ovarian cancer risk reduction through opportunistic salpingectomy. J Gynecol Oncol 2015;26:83-86.KwonJSOvarian cancer risk reduction through opportunistic salpingectomy201526838610.3802/jgo.2015.26.2.83439723625872888Search in Google Scholar
Finlayson S for the BC’s Ovarian Cancer Research Team. Advocating Fallopian Tube removal at the time of hysterectomy to prevent ovarian cancer. http://www.ovcare.ca/prevention/for_health_professionals Dostęp: 01.10.2018.http://www.ovcare.ca/prevention/for_health_professionalsDostęp: 01.10.2018Search in Google Scholar
Lin YJ, Ou YC, Huang FJ, Lin PY, Kung FT, Lan KC. Ovarian response to gonadotropins in patients with tubal factor infertility: salpingectomy versus nonsalpingectomy. J Minim Invasive Gynecol 2013;20:637-641.LinYJOuYCHuangFJLinPYKungFTLanKCOvarian response to gonadotropins in patients with tubal factor infertility: salpingectomy versus nonsalpingectomy20132063764110.1016/j.jmig.2013.04.00523706676Search in Google Scholar
Skorupska KA, Miotła P. Are there any differences in quality of life and sexual functions after various types of hysterectomy – does prophylactic salpingectomy matter? Ginekol Pol 2016;87:26-31.SkorupskaKAMiotłaPAre there any differences in quality of life and sexual functions after various types of hysterectomy – does prophylactic salpingectomy matter?201687263110.17772/gp/6055427306465Search in Google Scholar
Dilley SE, Havrilesky LJ, Bakkum-Gamez J, Cohn DE, Straughn Jr JM, Caughey AB, Rodriguez MI. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol 2017;146:373-379.DilleySEHavrileskyLJBakkum-GamezJCohnDEStraughnJr JMCaugheyABRodriguezMI.Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention201714637337910.1016/j.ygyno.2017.05.03428577884Search in Google Scholar
Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD et al. for the Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296:185-192.FinchABeinerMLubinskiJLynchHTMollerPRosenBMurphyJGhadirianPFriedmanEFoulkesWDet alfor the Hereditary Ovarian Cancer Clinical Study Group200629618519210.1001/jama.296.2.18516835424Search in Google Scholar
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-975.DomchekSMFriebelTMSingerCFEvansDGLynchHTIsaacsCGarberJENeuhausenSLMatloffEEelesRet alAssociation of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality201030496797510.1001/jama.2010.1237294852920810374Search in Google Scholar
Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J for the Kommission Ovar of the Gynecologic Oncology Study Group (AGO). Should fallopian tubes be removed during hysterectomy procedures? – A statement by AGO Ovar / Sollen die Tuben im Rahmen der Hysterektomie entfernt werden? – Ein Statement der AGO Ovar. Geburtshilfe Frauenheilkd 2015;75:339-341.PölcherMHauptmannSFotopoulouCSchmalfeldtBMeinhold-HeerleinIMusteaARunnebaumISehouliJfor the Kommission Ovar of the Gynecologic Oncology Study Group (AGO). Should fallopian tubes be removed during hysterectomy procedures? – A statement by AGO Ovar / Sollen die Tuben im Rahmen der Hysterektomie entfernt werden? – Ein Statement der AGO Ovar20157533934110.1055/s-0035-1545958443775226028692Search in Google Scholar
Finch A, Narod SA. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review. Maturitas 2011;70:261-265.FinchANarodSAQuality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review20117026126510.1016/j.maturitas.2011.08.00121893388Search in Google Scholar
Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C, Demsky R, Murphy J, Rosen B, Narod SA. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011;121:163-168.FinchAMetcalfeKAChiangJKElitLMcLaughlinJSpringateCDemskyRMurphyJRosenBNarodSAThe impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation201112116316810.1016/j.ygyno.2010.12.32621216453Search in Google Scholar
National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.Dostęp 26.10.2018.https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.Dostęp26.10.2018Search in Google Scholar
National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf Dostęp: 26.10.2018.https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdfDostęp: 26.10.2018Search in Google Scholar
Dawson A, Fernandez ML, Anglesio M, Yong PJ, Carey MS. Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. Ecancermedicalscience 2018;12:803.DawsonAFernandezMLAnglesioMYongPJCareyMSEndometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development20181280310.3332/ecancer.2018.803581391929456620Search in Google Scholar